Sahajanand Medical Technologies Ltd IPO

Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs). The Company focuses on research and development, precision manufacturing and clinically supported product innovation. Its flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology.

The Company operates three manufacturing facilities, two in India and one in Thailand, supported by two R&D centres in India and Thailand. As of June 30, 2026, it had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India. Its products were marketed in 77 countries in Fiscal 2026, through direct, hybrid and distributor-led models, with established market presence in India, Europe and other international markets.

The Company reported revenue from operations of ₹12,105.04 million in Fiscal 2026, compared with ₹10,248.79 million in Fiscal 2025 and ₹9,016.04 million in Fiscal 2024.

As of June 30, 2026, it had 1,605 full-time employees, 31 consultants and 707 contract-based employees. 

Competitive Strengths

• Extensive global sales and marketing network.
• Strong research and development capabilities.
• Diversified and integrated manufacturing facilities.
• Leadership in India and key international markets.
• Proven M&A and strategic collaboration capabilities.
• Technologically advanced medical devices in high-barrier segments.
• Experienced leadership team backed by reputed institutional investors.